A Phase 2 interventional study of PF-06741086 and PF-06741086 in Hemophilia A or B, sponsored by Pfizer. Completed at 10 sites in 6 countries. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-12-04.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.
Among the 47 studies in Hemophilia A by Pfizer, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2017, is one of 4 in phase 2, and was the 27th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 12–74
Pfizer · Sites in United States, India, Turkey
Ages 12–74 · Men only
Pfizer · Sites in United States, Australia, Canada and 10 more countries
Ages 18+ · Men only
Pfizer · Sites in United States, Argentina, Australia and 20 more countries
Ages 1–17 · Men only
Pfizer · Sites in United States, Argentina, Australia and 21 more countries
Ages 1–74 · Men only
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 64 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 5 started in 2017.
This study's enrollment of 27 is close to the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 34 across the 32 interventional studies, 52 across the 13 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Hemophilia A by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703606PfizerA Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. | 2027-05-05 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Hemophilia A by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: PF-06741086
Biological: PF-06741086
Biological: PF-06741086
Biological: PF-06741086
PF-06741086 subcutaneous (SC) injection
PF-06741086 SC injection
PF-06741086 SC injection
PF-06741086 SC injection
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.
Time frame: Study Day 1 to Day 113 Visit
Number of Participants Discontinued From Study Due to TEAEs
An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
Time frame: Study Day 1 to Day 113 Visit
Number of Participants With Abnormal Laboratory Findings-Hematology
Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: \<0.8\*lower limit of normal (LLN) or \<0.8\*Baseline(Baseline \<1.0\*LLN); for platelets: \<100,000\*10\^3/mm\^3 or \<= 0.77\*Baseline (Baseline \<1.0\*LLN).
Time frame: Baseline to Study Day 113 Visit
Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry
Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.
Time frame: Baseline to Study Day 113
Number of Participants With Abnormal Laboratory Findings-Urinalysis
Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.
Time frame: Baseline to Study Day 113 Visit
Change From Baseline for Globulin by Dose Cohort
Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.
Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort
Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).
Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort
The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.
Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Change From Baseline for Fibrinogen by Dose Cohort
Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
Time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
Change From Baseline for Antithrombin III by Dose Cohort
Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.
Time frame: Baseline, Study Day 8, 15, 22 and 29.
Change From Baseline for Troponin I by Dose Cohort
Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.
Time frame: Baseline, Study Day 8, 15, 22, 29, 57 and 85.
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value \<90 mm Hg or change \>=30 mm Hg increase; 2) Supine diastolic BP: value \<50 mm Hg or change \>=20 mm Hg increase; 3) Supine pulse rate: value \<40 beats/min or \>120 beats/min.
Time frame: Baseline to Study Day 113 Visit
Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria
Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline \>200 msec and increase of \>=25%; PR interval baseline \<=200 msec and increase of \>=50%; QRS interval increase of \>=50%. Only the number of participants meeting pre-defined criteria was reported below.
Time frame: Baseline to Study Day 29 Visit.
Number of Participants With Clinically Significant Changes in Physical Examination Findings
Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.
Time frame: Baseline to Study Day 113 Visit
Number of Participants With Infusion and Injection Site Reactions
Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (\< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.
Time frame: Baseline to Study Day 113 Visit
Annualized Bleeding Rate (ABR)
Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / (\[last dose date + 9 - first dose date + 1\] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 \<=age \<=65 and factor activity \<=1%).
Time frame: Pre-treatment: within 6 months prior to study enrollment; On-study: Day 1 to 9 days after the last dose (Day 78)
Plasma PF-06741086 Concentrations
Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.
Time frame: pre-dose on Study Day 1, 24hours (h), 72h post Study Day 1 dosing, pre-dose on Study Day 8, 15 and 22, pre-dose on Study Day 29, 24h, 96h post Study Day 29 dosing, pre-dose on Study Day 57, 168h, 840h post Study Day 57 dosing
Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086
AUClast was calculated by linear/Log trapezoidal method.
Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing
Maximum Plasma Concentration (Cmax) of PF-06741086
Cmax was observed directly from data.
Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086
Cmin was observed directly from data.
Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086
Tmax was observed directly from data as time of first occurrence.
Time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086
The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.
Time frame: Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Apparent Clearance After Oral Dose (CL/F) of PF-06741086
CL/F was calculated by dose/AUCtau.
Time frame: Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)
Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Change From Baseline in Thrombin Generation (TGA) Lag Time
An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Change From Baseline in Thrombin Generation (TGA) Peak
An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Change From Baseline in Endogenous Thrombin Generation (TGA) Potential
An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Change From Baseline in Prothrombin Fragments 1 + 2
An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Change From Baseline in D-Dimer
An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Change From Baseline in Dilute Prothrombin Time
An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.
Time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)
Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer \>=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.
Time frame: Baseline up to Study Day 113
Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)
Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.
Time frame: Baseline up to Study Day 113
| Milestone | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor |
|---|---|---|---|---|
| Started | 7 | 6 | 6 | 7 |
| Completed | 7 | 5 | 6 | 6 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| All-causalities TEAE | 7 | 4 | 6 | 4 | 11 | 21 |
| Treatment-related TEAE | 4 | 4 | 3 | 3 | 7 | 14 |
| All-causalities serious TEAE | 1 | 1 | 1 | 1 | 2 | 4 |
| Treatment-related serious TEAE | 0 | 0 | 0 | 0 | 0 | 0 |
| All-causalities Grade 3 or 4 TEAE | 0 | 0 | 2 | 2 | 2 | 4 |
| Treatment-related Grade 3 or 4 TEAE | 0 | 0 | 2 | 2 | 2 | 4 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| All-causalities TEAE | 0 | 1 | 0 | 1 | 1 | 2 |
| Treatment-related TEAE | 0 | 1 | 0 | 1 | 1 | 2 |
Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: \<0.8\*lower limit of normal (LLN) or \<0.8\*Baseline(Baseline \<1.0\*LLN); for platelets: \<100,000\*10\^3/mm\^3 or \<= 0.77\*Baseline (Baseline \<1.0\*LLN).
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Hemoglobin meeting pre-defined criteria | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit meeting pre-defined criteria | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythrocytes <0.8*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets meeting pre-defined criteria | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes <0.6*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes >1.5*upper limit of normal (ULN) | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes <0.8*LLN | 0 | 1 | 0 | 0 | 0 | 1 |
| Lymphocytes >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils <0.8*LLN | 1 | 2 | 0 | 0 | 1 | 3 |
| Neutrophils >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Basophils >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Monocytes >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Bilirubin >1.5*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin >1.5*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Indirect Bilirubin >1.5*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase >3.0*ULN | 0 | 0 | 1 | 0 | 0 | 1 |
| Alanine Aminotransferase >3.0*ULN | 1 | 1 | 1 | 0 | 1 | 3 |
| Gamma Glutamyl Transferase >3.0*ULN | 0 | 1 | 0 | 0 | 0 | 1 |
| Alkaline Phosphatase | 0 | 0 | 0 | 0 | 0 | 0 |
| Protein <0.8*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Protein >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin <0.8*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin >1.2*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen >1.3*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine >1.3*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Urate >1.2*ULN | 0 | 0 | 0 | 2 | 2 | 2 |
| Triglycerides >1.3*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium <0.95*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium >1.05*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium <0.9*LLN | 1 | 0 | 0 | 0 | 1 | 1 |
| Potassium >1.1*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride <0.9*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride >1.1*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium <0.9*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium >1.1*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Bicarbonate <0.9*LLN | 2 | 1 | 0 | 0 | 2 | 3 |
| Bicarbonate >1.1*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose <0.6*LLN | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose >1.5*ULN | 0 | 0 | 2 | 1 | 1 | 3 |
| Creatine Kinase >2.0*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Troponin I >1.0*ULN | 1 | 1 | 0 | 2 | 3 | 4 |
| Cholesterol >1.3*ULN | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrinogen <=0.5*LLN or <=0.5*baseline | 0 | 0 | 0 | 1 | 1 | 1 |
Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| pH (Scalar) <4.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| pH (Scalar) >8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine glucose >=1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Ketones (Scalar) >=1 | 0 | 0 | 1 | 1 | 1 | 2 |
| Urine protein >=1 | 0 | 0 | 0 | 1 | 1 | 1 |
| Urine hemoglobin (Scalar) >=1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urobilinogen >=1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine bilirubin (Scalar) >=1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nitrite (Scalar) >=1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocyte esterase (Scalar) >=1 | 1 | 1 | 0 | 1 | 2 | 3 |
| Urine erythrocytes (/HPF) >=20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine leukocytes (/HPF) >=20 | 0 | 1 | 0 | 1 | 1 | 2 |
| Bacteria (/HPF) >20 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.
| gram/liter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Globulin, Change at Day 8 | -0.3 ± 3.04 | -1.7 ± 3.93 | -1.3 ± 2.73 | 0.4 ± 2.51 | 0.1 ± 2.70 | -0.7 ± 3.01 |
| Globulin, Change at Day 15 | -0.7 ± 2.06 | -0.8 ± 2.32 | -1.3 ± 2.50 | -1.3 ± 3.35 | -1.0 ± 2.69 | -1.0 ± 2.47 |
| Globulin, Study Day 22 | -1.6 ± 2.82 | -0.5 ± 1.52 | -1.5 ± 3.08 | -0.6 ± 4.12 | -1.1 ± 3.43 | -1.0 ± 2.93 |
| Globulin, Change at Day 29 | -0.3 ± 3.27 | -0.3 ± 3.08 | 0.2 ± 1.10 | -1.3 ± 2.75 | -0.8 ± 2.91 | -0.5 ± 2.62 |
| Globulin, Change at Day 57 | 0.7 ± 3.72 | 1.8 ± 2.99 | -0.3 ± 1.63 | -0.7 ± 2.94 | 0.0 ± 3.28 | 0.4 ± 2.90 |
| Globulin, Change at Day 85 | 1.3 ± 3.15 | -1.4 ± 4.77 | -0.5 ± 3.02 | 1.0 ± 2.61 | 1.2 ± 2.79 | 0.2 ± 3.35 |
| Globulin, Change at Day 113 | -0.3 ± 3.15 | -1.2 ± 4.67 | 0.5 ± 2.65 | -0.8 ± 3.06 | -0.5 ± 2.99 | -0.5 ± 3.33 |
Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).
| Ratio | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| PT/INR, Change at Day 8 | -0.03 ± 0.049 | -0.02 ± 0.041 | 0.05 ± 0.138 | 0.03 ± 0.138 | 0.00 ± 0.104 | 0.01 ± 0.102 |
| PT/INR, Change at Day 15 | 0.03 ± 0.076 | 0.00 ± 0.063 | 0.02 ± 0.041 | 0.00 ± 0.082 | 0.01 ± 0.077 | 0.01 ± 0.065 |
| PT/INR, Change at Day 22 | 0.03 ± 0.095 | 0.00 ± 0.063 | -0.02 ± 0.041 | -0.01 ± 0.069 | 0.01 ± 0.083 | 0.00 ± 0.069 |
| PT/INR, Change at Day 29 | 0.03 ± 0.082 | -0.02 ± 0.041 | 0.00 ± 0.063 | 0.00 ± 0.115 | 0.02 ± 0.099 | 0.00 ± 0.079 |
| PT/INR, Change at Day 57 | 0.00 ± 0.126 | -0.03 ± 0.052 | 0.00 ± 0.063 | -0.02 ± 0.075 | -0.01 ± 0.100 | -0.01 ± 0.080 |
| PT/INR, Change at Day 85 | -0.01 ± 0.107 | 0.04 ± 0.152 | -0.02 ± 0.075 | -0.03 ± 0.082 | -0.02 ± 0.093 | -0.01 ± 0.102 |
| PT/INR, Change at Day 113 | 0.06 ± 0.127 | -0.03 ± 0.052 | -0.05 ± 0.058 | 0.07 ± 0.052 | 0.06 ± 0.096 | 0.02 ± 0.094 |
The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.
| seconds | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| aPTT, Change at Day 8 | 8.49 ± 17.017 | 10.63 ± 11.634 | 11.03 ± 15.467 | -12.26 ± 7.082 | -1.89 ± 16.512 | 3.98 ± 16.079 |
| aPTT, Change at Day 15 | 9.50 ± 10.907 | 12.50 ± 15.303 | 1.20 ± 20.075 | -10.26 ± 6.757 | -0.38 ± 13.457 | 2.96 ± 15.825 |
| aPTT, Change at Day 22 | 14.79 ± 10.799 | 12.15 ± 15.232 | 4.50 ± 9.765 | -11.77 ± 11.247 | 1.51 ± 17.381 | 4.65 ± 15.543 |
| aPTT, Change at Day 29 | 13.42 ± 11.102 | 9.85 ± 15.999 | 10.13 ± 10.250 | -12.87 ± 11.390 | -0.74 ± 17.386 | 4.41 ± 16.009 |
| aPTT, Change at Day 57 | 13.65 ± 13.378 | 14.25 ± 14.061 | 7.82 ± 11.580 | -9.13 ± 8.390 | 2.26 ± 15.966 | 6.65 ± 14.817 |
| aPTT, Change at Day 85 | 9.00 ± 10.928 | 3.84 ± 18.089 | 7.68 ± 14.733 | -7.57 ± 10.124 | 1.35 ± 13.278 | 3.45 ± 14.257 |
| aPTT, Change at Day 113 | 8.46 ± 23.391 | 0.78 ± 16.332 | -0.97 ± 26.633 | 9.37 ± 20.265 | 8.88 ± 21.093 | 5.05 ± 20.500 |
Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
| milligram/deciliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Fibrinogen, Change at Day 8 | -49.7 ± 28.72 | -59.7 ± 38.20 | -3.5 ± 24.16 | -54.4 ± 59.58 | -52.1 ± 45.00 | -42.6 ± 44.14 |
| Fibrinogen, Change at Day 15 | -59.4 ± 41.28 | -51.0 ± 31.84 | -8.3 ± 25.96 | -85.6 ± 94.86 | -72.5 ± 71.58 | -52.7 ± 60.78 |
| Fibrinogen, Change at Day 22 | -72.0 ± 40.76 | -36.8 ± 44.93 | -33.2 ± 32.41 | -87.9 ± 115.49 | -79.9 ± 83.61 | -59.2 ± 69.08 |
| Fibrinogen, Change at Day 29 | -84.7 ± 43.53 | -40.0 ± 26.57 | -40.3 ± 20.99 | -99.9 ± 106.59 | -92.8 ± 80.82 | -67.6 ± 65.01 |
| Fibrinogen, Change at Day 57 | -33.5 ± 85.81 | 10.0 ± 79.34 | -21.3 ± 24.23 | -58.7 ± 71.81 | -46.1 ± 76.57 | -25.9 ± 69.68 |
| Fibrinogen, Change at Day 85 | -49.9 ± 47.93 | -39.4 ± 63.27 | -10.5 ± 44.94 | -40.8 ± 74.28 | -45.7 ± 58.91 | -35.6 ± 56.31 |
| Fibrinogen, Change at Day 113 | -38.6 ± 44.48 | -5.2 ± 29.34 | 23.5 ± 26.80 | -61.7 ± 126.18 | -49.2 ± 88.13 | -25.1 ± 73.56 |
Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.
| Percentage of activity of AT in plasma | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Antithrombin III, Change at Day 8 | 2.1 ± 5.18 | -1.8 ± 7.05 | 3.7 ± 7.58 | -7.3 ± 9.32 | -2.6 ± 8.74 | -1.0 ± 8.24 |
| Antithrombin III, Change at Day 15 | 2.4 ± 16.96 | 0.5 ± 8.14 | -15.3 ± 16.45 | -6.9 ± 6.74 | -2.2 ± 13.30 | -4.6 ± 14.02 |
| Antithrombin III, Change at Day 22 | -7.6 ± 17.55 | 5.2 ± 12.69 | -5.3 ± 9.97 | -4.4 ± 17.61 | -6.0 ± 16.97 | -3.3 ± 14.97 |
| Antithrombin III, Change at Day 29 | -0.8 ± 8.04 | -4.3 ± 11.55 | -10.3 ± 15.45 | -12.7 ± 12.96 | -7.2 ± 12.20 | -7.3 ± 12.51 |
Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.
| nanogram/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Troponin I, Change at Day 8 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Troponin I, Change at Day 15 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Troponin I, Change at Day 22 | 0.0042 ± 0.01021 | 0 ± 0 | 0 ± 0 | 0.0142 ± 0.03470 | 0.0092 ± 0.02494 | 0.0052 ± 0.01907 |
| Troponin I, Change at Day 29 | 0 ± 0 | 0.0113 ± 0.02250 | 0 ± 0 | 0.0121 ± 0.03213 | 0.0065 ± 0.02357 | 0.0059 ± 0.02010 |
| Troponin I, Change at Day 57 | — | 0 | — | — | — | 0 |
| Troponin I, Change at Day 85 | 0 | — | — | — | 0 | 0 |
Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value \<90 mm Hg or change \>=30 mm Hg increase; 2) Supine diastolic BP: value \<50 mm Hg or change \>=20 mm Hg increase; 3) Supine pulse rate: value \<40 beats/min or \>120 beats/min.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Supine systolic BP value <90 mm Hg | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine systolic BP change >=30 mm Hg increase | 0 | 1 | 1 | 0 | 0 | 2 |
| Supine diastolic BP value <50 mm Hg | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine diastolic BP change >=20 mm Hg increase | 0 | 1 | 0 | 0 | 0 | 1 |
| Supine pulse rate value <40 beats/min | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine pulse rate value >120 beats/min | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline \>200 msec and increase of \>=25%; PR interval baseline \<=200 msec and increase of \>=50%; QRS interval increase of \>=50%. Only the number of participants meeting pre-defined criteria was reported below.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria | 0 | 0 | 0 | 0 | 0 | 0 |
Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examination Findings | 0 | 0 | 0 | 0 | 0 | 0 |
Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (\< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| All-causality Mild | 3 | 1 | 0 | 1 | 4 | 5 |
| Treatment-related Mild | 3 | 1 | 0 | 1 | 4 | 5 |
| All-causality Moderate | 0 | 0 | 0 | 1 | 1 | 1 |
| Treatment-related Moderate | 0 | 0 | 0 | 1 | 1 | 1 |
| All-causality Severe | 0 | 0 | 2 | 0 | 0 | 2 |
| Treatment-related Severe | 0 | 0 | 2 | 0 | 0 | 2 |
Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / (\[last dose date + 9 - first dose date + 1\] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 \<=age \<=65 and factor activity \<=1%).
| Bleeding episodes per year | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Pre-Treatment | 23.00 ± 7.457 | 14.67 ± 1.633 | 20.33 ± 10.838 | 17.33 ± 3.011 | 20.17 ± 6.177 | 18.83 ± 7.100 |
| On-Study | 4.22 ± 3.799 | 1.62 ± 2.533 | 4.17 ± 6.467 | 0.65 ± 1.603 | 2.43 ± 3.345 | 2.67 ± 4.092 |
Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.
| nanogram/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| 24h post Day 1 dosing | 12180 ± 8500.2 | 15620 ± 8055.3 | 11640 ± 4670.6 | 18130 ± 9111.3 | 15150 ± 9011.0 |
| 72h post Day 1 dosing | 17560 ± 10637 | 20850 ± 8433.7 | 24270 ± 8018.9 | 20640 ± 8978.4 | 19100 ± 9591.3 |
| Pre-dose on Day 8 | 11290 ± 10019 | 14060 ± 6201.2 | 16700 ± 5689.1 | 11940 ± 4981.7 | 11610 ± 7609.2 |
| Pre-dose on Day 15 | 22850 ± 15142 | 16680 ± 7668.8 | 28180 ± 10163 | 24870 ± 5726.8 | 23860 ± 11048 |
| Pre-dose on Day 22 | 33010 ± 19724 | 17900 ± 10509 | 41200 ± 17504 | 36450 ± 10432 | 34600 ± 15590 |
| Pre-dose on Day 29 | 46180 ± 21357 | 16780 ± 7939.7 | 59950 ± 30625 | 41500 ± 13884 | 43840 ± 17161 |
| 24h post Day 29 dosing | 66500 ± 27135 | 23530 ± 8548.4 | 73780 ± 22425 | 69920 ± 27902 | 68210 ± 26010 |
| 96h post Day 29 dosing | 69130 ± 30459 | 20680 ± 11580 | 74950 ± 27538 | 58150 ± 18753 | 62860 ± 22794 |
| Pre-dose on Day 57 | 54580 ± 29022 | 18260 ± 15062 | 66480 ± 45529 | 59140 ± 24377 | 56860 ± 25382 |
| 168h post Day 57 dosing | 53890 ± 43483 | 24800 ± 2994.4 | 87500 ± 37163 | 66700 ± 28971 | 60300 ± 35481 |
| 840h post Day 57 dosing | 586.6 ± 1318.4 | — | — | 90.00 ± 180.00 | 406.0 ± 1056.1 |
AUClast was calculated by linear/Log trapezoidal method.
| nanogram*hour/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086 | 1818000 ± 79 | 2675000 ± 41 | 2806000 ± 37 | 2495000 ± 40 | 2130000 ± 61 |
Cmax was observed directly from data.
| nanogram/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Cmax, Day 1 | 14880 ± 70 | 19480 ± 42 | 23070 ± 37 | 19680 ± 51 | 17110 ± 61 |
| Cmax, Day 29 | 61850 ± 47 | 24150 ± 44 | 73490 ± 38 | 66070 ± 44 | 63930 ± 43 |
Cmin was observed directly from data.
| nanogram/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Cmin, Day 1 | 7980 ± 112 | 13040 ± 43 | 15660 ± 44 | 11140 ± 41 | 9429 ± 78 |
| Cmin, Day 29 | 42120 ± 52 | 15000 ± 59 | 53630 ± 61 | 39490 ± 37 | 40790 ± 42 |
Tmax was observed directly from data as time of first occurrence.
| hours | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Tmax, Day 1 | 70.0 (69.1 to 72.8) | 69.7 (68.2 to 71.1) | 71.6 (67.6 to 72.3) | 70.7 (22.8 to 167) | 70.1 (22.8 to 167) |
| Tmax, Day 29 | 23.7 (23.1 to 94.2) | 23.7 (22.0 to 71.7) | 58.5 (23.3 to 97.0) | 22.8 (22.1 to 94.7) | 23.3 (22.1 to 94.7) |
The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.
| nanogram*hour/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086 | 9045000 ± 49 | 3309000 ± 50 | 11090000 ± 43 | 9248000 ± 38 | 9146000 ± 41 |
CL/F was calculated by dose/AUCtau.
| milliliter/hour | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Apparent Clearance After Oral Dose (CL/F) of PF-06741086 | 33.16 ± 49 | 45.34 ± 50 | 40.60 ± 43 | 32.43 ± 38 | 32.79 ± 41 |
Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.
| nanogram/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| TFPI, Change at Day 2 | 3.9 ± 31.43 | -13.4 ± 17.17 | 8.2 ± 19.83 | 0.4 ± 46.81 | 2.1 ± 38.35 |
| TFPI, Change at Day 4 | 39.4 ± 46.10 | 43.2 ± 25.76 | 74.0 ± 22.03 | 86.0 ± 29.71 | 62.7 ± 44.41 |
| TFPI, Change at Day 8 | 42.7 ± 82.52 | 72.4 ± 10.81 | 120.5 ± 34.41 | 55.9 ± 69.84 | 49.3 ± 73.76 |
| TFPI, Change at Day 15 | 143.9 ± 107.56 | 78.8 ± 43.36 | 186.5 ± 52.80 | 156.1 ± 83.87 | 150.0 ± 92.88 |
| TFPI, Change at Day 22 | 256.1 ± 137.09 | 110.0 ± 80.96 | 301.5 ± 84.39 | 223.3 ± 128.08 | 239.7 ± 128.59 |
| TFPI, Change at Day 29 | 324.2 ± 127.46 | 106.6 ± 77.56 | 334.7 ± 120.67 | 222.1 ± 135.29 | 269.2 ± 136.83 |
| TFPI, Change at Day 30 | 363.8 ± 156.87 | 115.6 ± 86.41 | 347.8 ± 170.70 | 286.7 ± 103.72 | 325.3 ± 133.04 |
| TFPI, Change at Day 33 | 337.7 ± 129.05 | 165.8 ± 35.20 | 351.0 ± 161.54 | 296.3 ± 112.30 | 317.0 ± 117.34 |
| TFPI, Change at Day 57 | 383.3 ± 137.17 | 140.0 ± 126.96 | 460.5 ± 247.37 | 371.0 ± 178.73 | 377.2 ± 152.03 |
| TFPI, Change at Day 85 | 396.7 ± 216.54 | 246.7 ± 51.81 | 492.2 ± 308.46 | 425.0 ± 266.57 | 409.8 ± 230.80 |
| TFPI, Change at Day 113 | 30.0 ± 72.30 | 41.5 ± 28.99 | 39.0 ± 16.15 | -14.0 ± 33.17 | 9.7 ± 59.94 |
An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.
| minutes | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| TGA lag time, Change at Day 2 | -7.16 ± 5.865 | -2.77 ± 1.517 | -3.93 ± 1.919 | -4.13 ± 1.238 | -5.64 ± 4.365 |
| TGA lag time, Change at Day 4 | -6.80 ± 6.079 | -2.80 ± 1.399 | -3.48 ± 1.957 | -4.17 ± 1.501 | -5.49 ± 4.467 |
| TGA lag time, Change at Day 8 | -6.94 ± 5.882 | -2.88 ± 1.292 | -3.57 ± 2.018 | -4.43 ± 1.506 | -5.69 ± 4.327 |
| TGA lag time, Change at Day 15 | -6.90 ± 5.897 | -3.07 ± 1.221 | -3.27 ± 1.870 | -4.29 ± 1.342 | -5.59 ± 4.327 |
| TGA lag time, Change at Day 22 | -6.94 ± 5.978 | -2.80 ± 1.585 | -3.12 ± 2.097 | -4.34 ± 1.638 | -5.64 ± 4.422 |
| TGA lag time, Change at Day 29 | -5.33 ± 4.871 | -2.77 ± 1.392 | -3.43 ± 2.016 | -4.32 ± 1.781 | -4.83 ± 3.537 |
| TGA lag time, Change at Day 30 | -5.22 ± 4.893 | -2.77 ± 1.372 | -3.50 ± 2.082 | -4.48 ± 1.681 | -4.88 ± 3.640 |
| TGA lag time, Change at Day 33 | -5.08 ± 4.414 | -2.40 ± 1.568 | -3.35 ± 2.261 | -4.52 ± 1.771 | -4.83 ± 3.329 |
| TGA lag time, Change at Day 57 | -4.73 ± 4.711 | -2.28 ± 2.020 | -3.42 ± 1.962 | -3.78 ± 1.376 | -4.26 ± 3.346 |
| TGA lag time,Change at Day 85 | -6.34 ± 5.745 | -3.10 ± 1.344 | -3.27 ± 2.014 | -3.33 ± 1.755 | -4.95 ± 4.497 |
| TGA lag time, Change at Day 113 | -0.79 ± 7.428 | 0.80 ± 0.283 | 1.53 ± 5.306 | 0.78 ± 5.251 | -0.06 ± 6.304 |
An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.
| nanomole | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| TGA peak, Change at Day 2 | 72.93 ± 35.734 | 70.92 ± 23.721 | 68.18 ± 15.693 | 63.41 ± 9.743 | 68.17 ± 25.642 |
| TGA peak, Change at Day 4 | 60.00 ± 30.196 | 59.28 ± 30.156 | 50.87 ± 20.687 | 51.79 ± 14.929 | 55.89 ± 23.278 |
| TGA peak, Change at Day 8 | 49.36 ± 32.033 | 56.00 ± 33.636 | 50.30 ± 14.019 | 54.36 ± 15.007 | 51.86 ± 24.171 |
| TGA peak, Change at Day 15 | 49.01 ± 23.471 | 52.57 ± 28.440 | 46.40 ± 22.985 | 40.90 ± 7.886 | 44.96 ± 17.340 |
| TGA peak, Change at Day 22 | 44.50 ± 27.260 | 52.07 ± 33.558 | 38.15 ± 16.313 | 44.41 ± 22.567 | 44.46 ± 24.042 |
| TGA peak, Change at Day 29 | 42.95 ± 24.026 | 49.72 ± 29.316 | 38.23 ± 21.808 | 42.48 ± 23.057 | 42.72 ± 22.452 |
| TGA peak, Change at Day 30 | 35.93 ± 26.177 | 51.75 ± 29.276 | 37.72 ± 24.136 | 48.62 ± 21.427 | 41.70 ± 23.878 |
| TGA peak, Change at Day 33 | 76.68 ± 69.887 | 46.83 ± 37.084 | 36.25 ± 21.955 | 54.10 ± 28.276 | 66.42 ± 53.861 |
| TGA peak, Change at Day 57 | 37.13 ± 21.866 | 32.57 ± 20.368 | 34.67 ± 20.584 | 33.93 ± 7.688 | 35.53 ± 15.716 |
| TGA peak, Change at Day 85 | 37.60 ± 21.142 | 69.92 ± 40.250 | 30.15 ± 18.614 | 30.15 ± 22.743 | 34.16 ± 21.306 |
| TGA peak, Change at Day 113 | 24.37 ± 33.703 | 16.05 ± 36.557 | 43.33 ± 68.794 | 6.93 ± 15.334 | 16.32 ± 27.345 |
An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.
| nanomole*minute | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Endogenous TGA Potential, Change at Day 2 | 864.0 ± 250.60 | 816.8 ± 211.13 | 999.8 ± 249.59 | 1065.3 ± 161.71 | 964.6 ± 227.95 |
| Endogenous TGA Potential, Change at Day 4 | 766.7 ± 236.94 | 714.8 ± 275.75 | 808.7 ± 288.78 | 825.1 ± 294.44 | 795.9 ± 258.54 |
| Endogenous TGA Potential, Change at Day 8 | 691.9 ± 301.43 | 659.8 ± 295.11 | 796.5 ± 151.00 | 918.6 ± 276.26 | 805.2 ± 301.66 |
| Endogenous TGA Potential, Change at Day 15 | 674.9 ± 244.61 | 608.5 ± 242.81 | 800.8 ± 334.99 | 639.3 ± 145.74 | 657.1 ± 194.32 |
| Endogenous TGA Potential, Change at Day 22 | 646.9 ± 295.05 | 589.0 ± 274.33 | 647.0 ± 236.38 | 731.4 ± 302.89 | 689.1 ± 290.60 |
| Endogenous TGA Potential, Change at Day 29 | 588.2 ± 239.00 | 623.0 ± 188.84 | 618.3 ± 276.51 | 660.5 ± 340.36 | 624.3 ± 282.93 |
| Endogenous TGA Potential, Change at Day 30 | 494.8 ± 247.86 | 672.0 ± 226.25 | 603.3 ± 332.44 | 710.2 ± 272.54 | 592.7 ± 270.33 |
| Endogenous TGA Potential, Change at Day 33 | 716.5 ± 391.60 | 606.0 ± 280.39 | 583.7 ± 291.25 | 848.8 ± 387.17 | 776.6 ± 376.05 |
| Endogenous TGA Potential, Change at Day 57 | 586.8 ± 200.04 | 445.2 ± 220.86 | 564.5 ± 287.43 | 579.7 ± 147.04 | 583.3 ± 167.42 |
| Endogenous TGA Potential, Change at Day 85 | 566.6 ± 202.22 | 812.2 ± 198.80 | 526.7 ± 297.03 | 493.7 ± 368.68 | 532.9 ± 280.20 |
| Endogenous TGA Potential, Change at Day 113 | 256.4 ± 347.91 | 50.5 ± 290.62 | 306.5 ± 440.04 | 142.3 ± 361.25 | 203.8 ± 344.10 |
An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.
| picomole/liter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Prothrombin fragments 1 + 2, Change at Day 2 | 430.0 ± 383.03 | 498.3 ± 484.40 | 275.7 ± 206.71 | 438.9 ± 507.68 | 434.4 ± 432.08 |
| Prothrombin fragments 1 + 2, Change at Day 4 | 548.1 ± 455.67 | 1096.7 ± 1403.57 | 574.5 ± 363.37 | 730.3 ± 537.21 | 639.2 ± 487.82 |
| Prothrombin fragments 1 + 2, Change at Day 8 | 450.3 ± 396.09 | 562.2 ± 605.07 | 413.0 ± 171.50 | 580.7 ± 259.63 | 515.5 ± 328.78 |
| Prothrombin fragments 1 + 2, Change at Day 15 | 481.7 ± 330.26 | 349.7 ± 212.59 | 389.2 ± 228.56 | 571.1 ± 474.23 | 526.4 ± 395.34 |
| Prothrombin fragments 1 + 2, Change at Day 22 | 608.1 ± 336.97 | 322.3 ± 161.76 | 420.2 ± 166.66 | 524.1 ± 577.08 | 566.1 ± 456.08 |
| Prothrombin fragments 1 + 2, Change at Day 29 | 650.3 ± 415.58 | 288.0 ± 259.19 | 577.7 ± 302.76 | 429.3 ± 257.91 | 531.3 ± 344.06 |
| Prothrombin fragments 1 + 2, Change at Day 30 | 655.7 ± 496.35 | 486.0 ± 608.26 | 521.0 ± 165.25 | 580.8 ± 507.83 | 618.3 ± 480.35 |
| Prothrombin fragments 1 + 2, Change at Day 33 | 761.3 ± 509.02 | 642.5 ± 759.02 | 1527.7 ± 2499.96 | 609.2 ± 380.74 | 685.3 ± 435.87 |
| Prothrombin fragments 1 + 2, Change at Day 57 | 586.5 ± 473.53 | 216.5 ± 173.44 | 465.3 ± 300.84 | 463.5 ± 397.57 | 525.0 ± 421.78 |
| Prothrombin fragments 1 + 2, Change at Day 85 | 588.3 ± 483.80 | 378.2 ± 207.16 | 470.2 ± 244.21 | 362.2 ± 378.54 | 483.9 ± 436.47 |
| Prothrombin fragments 1 + 2, Change at Day 113 | -6.6 ± 151.87 | 16.5 ± 19.09 | -75.5 ± 76.86 | -58.2 ± 121.15 | -30.4 ± 135.52 |
An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.
| microgram/milliliter | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| D-dimer, Change at Day 2 | 0.0393 ± 0.16303 | 0.0792 ± 0.22238 | 0.1900 ± 0.09301 | 0.1086 ± 0.30536 | 0.0739 ± 0.23790 |
| D-dimer, Change at Day 4 | 0.2050 ± 0.24491 | 0.2842 ± 0.36896 | 0.3217 ± 0.23248 | 0.6729 ± 0.62524 | 0.4389 ± 0.51676 |
| D-dimer, Change at Day 8 | 0.0743 ± 0.26111 | 0.2017 ± 0.29753 | 0.3292 ± 0.40635 | 0.5614 ± 0.54901 | 0.3179 ± 0.48422 |
| D-dimer, Change at Day 15 | 0.0979 ± 0.25666 | 0.1942 ± 0.28748 | 0.2500 ± 0.23424 | 0.1900 ± 0.82310 | 0.1439 ± 0.58769 |
| D-dimer, Change at Day 22 | 0.1364 ± 0.27802 | 0.2167 ± 0.33877 | 0.2000 ± 0.26109 | 0.1829 ± 1.27802 | 0.1596 ± 0.88887 |
| D-dimer, Change at Day 29 | 0.0633 ± 0.20029 | 0.2308 ± 0.32355 | 0.1517 ± 0.42347 | -0.0129 ± 1.17491 | 0.0223 ± 0.84172 |
| D-dimer, Change at Day 30 | 0.1350 ± 0.32388 | 0.1492 ± 0.26345 | 0.2133 ± 0.33914 | -0.0833 ± 1.31549 | 0.0258 ± 0.92048 |
| D-dimer, Change at Day 33 | 0.0800 ± 0.28796 | 0.1283 ± 0.37519 | 0.1233 ± 0.49855 | -0.1700 ± 1.68635 | -0.0450 ± 1.16076 |
| D-dimer, Change at Day 57 | 0.1942 ± 0.30049 | 0.2175 ± 0.22554 | 0.1233 ± 0.36122 | 0.4033 ± 0.37120 | 0.2988 ± 0.34001 |
| D-dimer, Change at Day 85 | 0.1664 ± 0.30521 | 0.5860 ± 1.00003 | 0.1833 ± 0.43840 | 0.2300 ± 0.60395 | 0.1958 ± 0.44682 |
| D-dimer, Change at Day 113 | -0.1000 ± 0.22127 | 0.1875 ± 0.26517 | 0.0175 ± 0.41838 | -0.7833 ± 1.60090 | -0.4154 ± 1.10366 |
An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.
| seconds | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC |
|---|---|---|---|---|---|
| Dilute prothrombin Time, Change at Day 2 | -27.84 ± 21.023 | -13.32 ± 25.780 | -31.25 ± 13.606 | -17.14 ± 26.167 | -22.49 ± 23.470 |
| Dilute prothrombin Time, Change at Day 4 | -30.03 ± 24.312 | -17.87 ± 20.042 | -34.50 ± 18.306 | -14.70 ± 30.971 | -22.36 ± 27.907 |
| Dilute prothrombin Time, Change at Day 8 | -23.63 ± 19.991 | -15.10 ± 22.129 | -31.23 ± 19.645 | -20.97 ± 33.969 | -22.30 ± 26.813 |
| Dilute prothrombin Time, Change at Day 15 | -20.73 ± 23.070 | -19.33 ± 20.853 | -33.53 ± 14.880 | 1.11 ± 27.208 | -9.81 ± 26.753 |
| Dilute prothrombin Time, Change at Day 22 | -21.40 ± 22.351 | -10.55 ± 16.057 | -26.78 ± 32.501 | -21.61 ± 30.842 | -21.51 ± 25.877 |
| Dilute prothrombin Time, Change at Day 29 | -15.32 ± 13.867 | -7.10 ± 20.643 | -40.40 ± 22.458 | -18.03 ± 24.600 | -16.78 ± 19.613 |
| Dilute prothrombin Time, Change at Day 30 | -13.27 ± 13.399 | -23.45 ± 19.413 | -45.18 ± 21.372 | -17.47 ± 25.729 | -15.37 ± 19.680 |
| Dilute prothrombin Time, Change at Day 33 | -23.35 ± 17.690 | -21.23 ± 20.010 | -29.10 ± 20.783 | -19.97 ± 19.297 | -21.66 ± 17.737 |
| Dilute prothrombin Time, Change at Day 57 | -14.75 ± 14.393 | -12.03 ± 30.806 | -26.80 ± 12.911 | -11.72 ± 42.872 | -13.23 ± 30.531 |
| Dilute prothrombin TIme, Change at Day 85 | -20.99 ± 25.424 | -25.80 ± 24.334 | -23.43 ± 26.166 | -12.42 ± 34.871 | -17.03 ± 29.148 |
| Dilute prothrombin Time, Change at Day 113 | -16.44 ± 13.578 | 14.30 ± 61.235 | -39.63 ± 20.182 | -12.78 ± 28.226 | -14.75 ± 20.682 |
Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer \>=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| ADA incidence | 0 | 1 | 2 | 0 | 0 | 3 |
| Participants with treatment induced ADA incidence | 0 | 1 | 2 | 0 | 0 | 3 |
| Participants with treatment boosted ADA incidence | 0 | 0 | 0 | 0 | 0 | 0 |
Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.
| Participants | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| NAb incidence | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with treatment induced NAb incidence | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with treatment boosted NAb incidence | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over 113 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06741086 300 mg SC QW Non-Inhibitor | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| PF-06741086 450 mg SC QW Non-Inhibitor | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| PF-06741086 300 mg SC QW Inhibitor | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Overall PF-06741086 300 mg SC | 0/14 (0%) | 2/14 (14.3%) | 10/14 (71.4%) |
| Total | 0/26 (0%) | 4/26 (15.4%) | 20/26 (76.9%) |
| Event | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/7 | 0/6 | 1/6 | 0/7 | 0/14 | 1/26 |
| Physical assaultSocial circumstances | 0/7 | 1/6 | 0/6 | 0/7 | 0/14 | 1/26 |
| Tooth socket haemorrhageGastrointestinal disorders | 0/7 | 0/6 | 0/6 | 1/7 | 1/14 | 1/26 |
| AppendicitisInfections and infestations | 1/7 | 0/6 | 0/6 | 0/7 | 1/14 | 1/26 |
| Event | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Overall PF-06741086 300 mg SC | Total |
|---|---|---|---|---|---|---|
| Injection site swellingGeneral disorders | 0/7 | 0/6 | 2/6 | 1/7 | 1/14 | 3/26 |
| HeadacheNervous system disorders | 0/7 | 0/6 | 2/6 | 0/7 | 0/14 | 2/26 |
| HypertensionVascular disorders | 0/7 | 2/6 | 1/6 | 0/7 | 0/14 | 3/26 |
| Injection site bruisingGeneral disorders | 2/7 | 0/6 | 0/6 | 0/7 | 2/14 | 2/26 |
| Abdominal painGastrointestinal disorders | 0/7 | 0/6 | 1/6 | 0/7 | 0/14 | 1/26 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/7 | 1/6 | 0/6 | 0/7 | 0/14 | 1/26 |
| FatigueGeneral disorders | 1/7 | 0/6 | 1/6 | 0/7 | 1/14 | 2/26 |
| Injection site indurationGeneral disorders | 1/7 | 0/6 | 1/6 | 0/7 | 1/14 | 2/26 |
| Injection site painGeneral disorders | 1/7 | 1/6 | 1/6 | 0/7 | 1/14 | 3/26 |
| Injection site warmthGeneral disorders | 0/7 | 0/6 | 1/6 | 0/7 | 0/14 | 1/26 |
Baseline analysis population included all participants who received at least 1 dose of study treatment.
| Age, Categorical(Participants) | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 6 | 6 | 7 | 26 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Total |
|---|---|---|---|---|---|
| Mean | 31.9 ± 8.17 | 28.7 ± 8.31 | 41.7 ± 15.87 | 44.1 ± 9.44 | 36.7 ± 12.05 |
| Sex: Female, Male(Participants) | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 7 | 6 | 6 | 7 | 26 |
| Race (NIH/OMB)(Participants) | PF-06741086 300 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor | PF-06741086 450 mg SC QW Non-Inhibitor | PF-06741086 300 mg SC QW Inhibitor | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 0 | 4 | 12 |
| White | 3 | 2 | 6 | 3 | 14 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2017 to primary completion in Dec 2018, 20 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 20 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Marstacimab